RXMD — Progressive Care Income Statement
0.000.00%
Last trade - 00:00
- $12.38m
- $6.68m
- $40.60m
- 59
- 78
- 13
- 48
C2018 December 31st | 2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 20.6 | 32.6 | 38.9 | 38.9 | 40.6 |
Cost of Revenue | |||||
Gross Profit | 4.69 | 7.97 | 8.96 | 10.2 | 9.7 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 22.2 | 33.6 | 39.5 | 39 | 42.8 |
Operating Profit | -1.54 | -0.935 | -0.554 | -0.19 | -2.15 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.63 | -2.5 | -1.44 | 0.218 | -5.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.63 | -2.51 | -1.45 | 0.218 | -5.9 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -1.63 | -2.51 | -1.45 | 0.218 | -5.9 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.63 | -2.51 | -1.45 | 0.218 | -6.45 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.779 | -1.16 | -0.794 | -0.265 | -2.31 |